Please wait
 
Joint Filing Agreement

The undersigned hereby agree that the Statement on Schedule 13G dated February 16, 2016 with respect to the shares of Common Stock of Aeolus Pharmaceuticals, Inc., and any further amendments thereto executed by each and any of the undersigned shall be filed on behalf of each of the undersigned pursuant to and in accordance with the provisions of Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended.

Dated:  February 16, 2016

BIOTECHNOLOGY VALUE FUND, L.P.
    
 
 
    
BVF INC.
By:
BVF Partners L.P., its general partner
    
 
By:
BVF Inc., its general partner
  
By:
/s/ Mark N. Lampert
 
 
    
Mark N. Lampert
By:
/s/ Mark N. Lampert
    
President
 
Mark N. Lampert
      
 
President
    
 
 
 
      
 
 
    
MARK N. LAMPERT
BIOTECHNOLOGY VALUE FUND II, L.P.
    
 
 
    
/s/ Mark N. Lampert
By:
BVF Partners L.P., its general partner
      
By:
BVF Inc., its general partner
      
 
 
      
By:
/s/ Mark N. Lampert
      
 
Mark N. Lampert
      
 
President
      
         
       
         
BVF PARTNERS L.P.
      
         
By:
BVF Inc., its general partner
      
 
 
      
By:
/s/ Mark N. Lampert
      
 
Mark N. Lampert
      
 
President
      

BVF INVESTMENTS, L.L.C.
      
         
By:
BVF Partners L.P., its manager
      
By:
BVF Inc., its general partner
      
         
By:
/s/ Mark N. Lampert
      
 
Mark N. Lampert
      
 
President
      

BVF PARTNERS OS LTD.
      
 
        
By:
BVF Partners L.P., its sole member
      
By:
BVF Inc., its general partner
      
 
 
      
By:
/s/ Mark N. Lampert
      
 
Mark N. Lampert
      
 
President
      
         
         
BIOTECHNOLOGY VALUE TRADING FUND OS LP
      
         
By:
BVF Partners L.P., its investment manager
      
By:
BVF Inc., its general partner
      
 
 
      
By:
/s/ Mark N. Lampert
      
 
Mark N. Lampert
      
 
President